Jupiter Neurosciences grants 100K options to director

JUPITER NEUROSCIENCES, INC. director Julie B. Kampf received a grant of stock options covering 100,000 shares of common stock.

Rhea-AI Filing Summary

JUPITER NEUROSCIENCES, INC. director Julie B. Kampf received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.

These options were granted under the company’s 2025 Equity Incentive Plan. They vest over three years in equal quarterly installments, beginning on September 2, 2026, as long as she continues to provide service through each vesting date. Following this grant, her reported option holdings from this award total 100,000 shares.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Kampf Julie B.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option — 100,000 contracts (Direct)

Footnotes (1)

1. F1. The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.

Key Figures

Option grant size: 100,000 options Exercise price: $0.2783 per share Underlying shares: 100,000 shares +2 more

5 metrics

Option grant size 100,000 options Stock options granted to director on June 2, 2026

Exercise price $0.2783 per share Strike price of director stock options

Underlying shares 100,000 shares Common stock underlying the option grant

Expiration date June 2, 2036 Option term end date

Total options after grant 100,000 options Total reported option holdings from this award following transaction

Key Terms

Stock Option, 2025 Equity Incentive Plan, vesting

3 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2025 Equity Incentive Plan financial

"The options were granted under the Issuer's 2025 Equity Incentive Plan."

vesting financial

"The options vest over three years commencing from September 2, 2026 in equal quarterly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did JUNS director Julie B. Kampf receive in this Form 4 filing?

Julie B. Kampf received a grant of stock options for 100,000 shares of Jupiter Neurosciences common stock. The options were awarded as compensation and give her the right to buy shares at a fixed exercise price if they vest and are exercised.

What is the exercise price of the stock options granted to the JUNS director?

The stock options were granted with an exercise price of $0.2783 per share. This means she can purchase Jupiter Neurosciences common stock at $0.2783 per share once the options vest and she chooses to exercise them in the future.

When do the Jupiter Neurosciences (JUNS) options start vesting for the director?

The options begin vesting on September 2, 2026. From that date, they vest in equal quarterly installments over three years, so portions become exercisable every quarter, subject to her continued service with Jupiter Neurosciences through each vesting date.

Over what period do the JUNS director stock options vest?

The options vest over three years in equal quarterly installments. This structure spreads vesting across multiple dates, helping align the director’s compensation with longer-term service and company performance, provided she remains in service through each vesting milestone.

When do the stock options granted to the JUNS director expire?

The stock options expire on June 2, 2036. If they are not exercised by that date, any unexercised portion will lapse, meaning the director will no longer have the right to purchase shares under this specific option grant.

Under which plan were the Jupiter Neurosciences (JUNS) options granted?

The options were granted under Jupiter Neurosciences’ 2025 Equity Incentive Plan. This plan is used to provide equity-based compensation, such as stock options, to directors and other participants to align their interests with shareholders over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kampf Julie B.

(Last) (First) (Middle)

C/O JUPITER NEUROSCIENCES, INC.

1001 NORTH US HYWAY 1, SUITE 504

(Street)

JUPITER FLORIDA 33477

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
JUPITER NEUROSCIENCES, INC. [ JUNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$0.2783	06/02/2026		A		100,000		(1)	06/02/2036	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.

	/s/ Julie B. Kampf	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)